Free Trial

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Receives Average Rating of "Buy" from Brokerages

Xenon Pharmaceuticals logo with Medical background

Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Get Free Report) has been given a consensus rating of "Buy" by the twelve analysts that are covering the stock, MarketBeat Ratings reports. Twelve analysts have rated the stock with a buy rating. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $54.82.

Several analysts recently commented on XENE shares. Royal Bank Of Canada cut their price objective on shares of Xenon Pharmaceuticals from $58.00 to $55.00 and set an "outperform" rating on the stock in a research report on Tuesday, May 13th. The Goldman Sachs Group cut their price objective on shares of Xenon Pharmaceuticals from $60.00 to $52.00 and set a "buy" rating on the stock in a research report on Thursday, April 17th. Evercore ISI started coverage on shares of Xenon Pharmaceuticals in a research report on Wednesday, May 14th. They set an "outperform" rating and a $55.00 price objective on the stock. Wall Street Zen downgraded shares of Xenon Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Wednesday, May 21st. Finally, Needham & Company LLC cut their price objective on shares of Xenon Pharmaceuticals from $60.00 to $55.00 and set a "buy" rating on the stock in a research report on Tuesday, May 13th.

Read Our Latest Stock Report on XENE

Institutional Trading of Xenon Pharmaceuticals

Institutional investors have recently made changes to their positions in the stock. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Xenon Pharmaceuticals during the 1st quarter valued at about $30,000. GF Fund Management CO. LTD. bought a new position in shares of Xenon Pharmaceuticals in the 4th quarter worth approximately $63,000. Quarry LP bought a new position in shares of Xenon Pharmaceuticals in the 4th quarter worth approximately $78,000. Magnetar Financial LLC bought a new position in shares of Xenon Pharmaceuticals in the 4th quarter worth approximately $210,000. Finally, Vident Advisory LLC bought a new position in shares of Xenon Pharmaceuticals in the 4th quarter worth approximately $212,000. Hedge funds and other institutional investors own 95.45% of the company's stock.

Xenon Pharmaceuticals Stock Performance

Shares of Xenon Pharmaceuticals stock traded up $0.30 during trading on Thursday, hitting $32.98. The company's stock had a trading volume of 732,810 shares, compared to its average volume of 637,230. The company has a fifty day simple moving average of $32.11 and a two-hundred day simple moving average of $35.28. The company has a market capitalization of $2.53 billion, a PE ratio of -10.21 and a beta of 1.10. Xenon Pharmaceuticals has a 52 week low of $26.74 and a 52 week high of $46.00.

Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last issued its quarterly earnings results on Monday, May 12th. The biopharmaceutical company reported ($0.83) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.90) by $0.07. The business had revenue of $7.50 million during the quarter, compared to the consensus estimate of $1.64 million. During the same quarter in the previous year, the business earned ($0.62) earnings per share. As a group, analysts predict that Xenon Pharmaceuticals will post -3.1 EPS for the current year.

Xenon Pharmaceuticals Company Profile

(Get Free Report

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.

See Also

Analyst Recommendations for Xenon Pharmaceuticals (NASDAQ:XENE)

Should You Invest $1,000 in Xenon Pharmaceuticals Right Now?

Before you consider Xenon Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xenon Pharmaceuticals wasn't on the list.

While Xenon Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Don’t Miss These Top 3 Defense Stocks Set To Gain
Triple-Digit Gains: These 4 Nuclear Stocks Have Even More Upside Ahead
3 Made in America Stocks Under $20 You Need to See!

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines